- Home
- ALT
ALT
Altimmune Inc.
as 10-31-2025 9:59am EST
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Upcoming Earnings Alert:
Get ready for potential market movements as Altimmune Inc. ALT prepares to release earnings report on 06 Nov 2025.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 348.6M | IPO Year: | N/A |
| Target Price: | $16.50 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.90 - $11.16 | Next Earning Date: | 11-06-2025 |
| Revenue: | $20,000 | Revenue Growth: | -95.11% |
| Revenue Growth (this year): | -65.26% | Revenue Growth (next year): | -58.43% |
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
Simply Wall St.
23 days ago
Pleasing Signs As A Number Of Insiders Buy Altimmune Stock
GlobeNewswire
a month ago
Altimmune to Participate in Two Upcoming Investor Conferences
GlobeNewswire
4 months ago
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
Insider Monkey
4 months ago
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial
MT Newswires
4 months ago
Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution
GlobeNewswire
4 months ago
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
GlobeNewswire
4 months ago
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
GlobeNewswire
5 months ago
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
Compare ALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.